AI Summary & Key Takeaways
AI InsightThese findings suggest that BA may have a preventive, rather than therapeutic, role in estrogen deficiency–related (OP).
📌 3 Key Takeaways
Abstract
Objective: Postmenopausal osteoporosis (OP) is characterized by estrogen deficiency–induced bone loss and deterioration of trabecular microarchitecture. Betulinic acid (BA), a natural pentacyclic triterpenoid, has demonstrated antioxidant and osteoprotective properties. This study aimed to evaluate the histopathological effects of BA on femoral bone tissue in ovariectomized rats. Methods: Thirty-two female Wistar albino rats were randomly divided into four groups (n=8): Sham, OVX, BA+OVX (BA administered before OVX), and OVX+BA (BA administered after OVX). BA was given orally at 3 mg/kg/day. Pelvic bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry (DEXA). Serum calcium levels were measured, and femoral bone tissues were evaluated histopathologically for trabecular thinning and loss of connectivity. Results: OVX resulted in a significant reduction in pelvic BMD and marked deterioration of trabecular bone architecture compared with the Sham group. BA administration prior to OVX significantly attenuated OVX-induced bone loss, as evidenced by higher pelvic BMD and preserved trabecular structure compared with the OVX group (p<.05). In contrast, BA treatment initiated after OVX did not significantly reverse bone loss or histopathological damage. Serum calcium levels did not differ significantly among the groups. Conclusion: BA exerts a protective effect against OVX-induced bone loss when administered prior to estrogen deficiency, preserving both bone mineral density and trabecular microarchitecture. These findings suggest that BA may have a preventive, rather than therapeutic, role in estrogen deficiency–related (OP).